Regulation of the Proto-oncogenes bcl-2 and c-myc by the Wilms' Tumor Suppressor Gene WT1

Cancer Research

Volumn 55, Issue 22, 1995, Pages 5386-5389

  Hewitt, Stephen M ^a   Hamada, Shinshichi ^a,c   Saunders, Grady F ^a   McDonnell, Timothy J ^a   Rauscher, Frank J ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b WISTAR INSTITUTE   (United States)

^c SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; GENE CONTROL; HUMAN; NEPHROBLASTOMA; ONCOGENE MYC; PRIORITY JOURNAL; PROTO ONCOGENE; TRANSCRIPTION REGULATION; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

AMINO ACID SEQUENCE; BASE SEQUENCE; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION; GENES, MYC; GENES, TUMOR SUPPRESSOR; HUMAN; KIDNEY NEOPLASMS; MOLECULAR SEQUENCE DATA; NEPHROBLASTOMA; PROMOTER REGIONS (GENETICS); PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENES; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TRANSCRIPTION FACTORS; WT1 PROTEINS;

EID: 0028844582     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Call, K. M., Glaser, T., Ito, C. Y., Buckler, A. J., Pelletier, J., Haber, D. A., Rose, E. A., Kral, A., Yeger, H., Lewis, W. H., Jones, C., and Housman, D. E. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms’ tumor locus. Cell, 60: 509–520, 1990.
2. Gessler, M., Poustka, A., Cavenee, W., Neve, R., Orkin, S., and Bruns, G. A. P. A zinc finer gene identified by chromosome jumping. Nature (Lond.), 343: 774–778, 1990.
3. Madden, S. L., Cook, D. M., Morris, J. F., Gashler, A., Sukhatme, V. P., and Rauscher, F. J., III. Transcriptional repression mediated by the WT1 Wilms tumor gene product. Science (Washington DC), 253: 1550–1553, 1991.
4. Drummond, I. A., Madden, S. L., Rohwer-Nutter, P., Bell, G. I., Sukhatme, V. P., and Rauscher, F. J., III. Repression of the insulin-like growth factor II gene by the Wilms tumor suppressor WT1. Science (Washington DC), 257: 674–678, 1992.
5. Wang, Z. Y., Madden, S. L., Deuel, T. F., and Rauscher, F. J., III. The Wilms’ tumor gene product, WT1, represses transcription of the platelet-derived growth factor A-chain gene. J. Biol. Chem., 267: 21999–22002, 1992.
6. Werner H., Rauscher, F. J., III, Sukhatme, V. P., Drummond, I. A., Roberts, C. T., Jr., and LeRoith, D. Transcriptional repression of the insulin-like growth factor I receptor (IGF-I-R) gene by the tumor suppressor WT1 involves binding to sequences both upstream and downstream of the IGF-I-R gene transcription start site. J. Biol. Chem., 269: 12577–12582, 1994.
7. Harrington M. A., Konicek, B., Song, A., Xia, X., Fredricks, W. J., and Rauscher, F. J., III. Inhibition of colony-stimulating factor-1 promoter activity by the products of the Wilms’ tumor locus. J. Biol. Chem., 268: 21271–21275, 1993.
8. Rupprecht H. D., Drummond, I. A., Madden, S. L., Ruascher, F. J., III, and Sukhatme, V. P. The Wilms’ tumor suppressor gene WT1 is negatively autoregulated. J. Biol. Chem., 269: 6189–6206, 1994.
9. Goodyer, P., Dehbi, M., Torban, E., Bruening, W., and Pelletier, J. Repression of the retinoic acid receptor-a gene by the Wilms’ tumor suppressor gene product, wtl. Oncogene, 10: 1125–1129, 1995.
10. Ryan, G., Steele-Perkins, V., Morris, J. F., Rauscher, F. J., III, and Dressier G. R. Repression of Pax-2 by WT1 during normal kidney development. Development, 121: 867–875, 1995.
11. Dey B. R., Sukhatme, V. P., Roberts, A. B., Sporn, M. B., Rauscher, F. J., III, and Kim, S.-J. Repression of the transforming growth factor-αl gene by the Wilms’ tumor suppressor WT1 gene product. Endocrinology, 8: 595–602, 1994.
12. Rauscher, I. I. I. F. J., Morris, J. F., Tournay, O. E., Cook, D. M., and Curran, T. Binding of the Wilms’ tumor locus zinc finger protein to the EGR-1 consensus sequence. Science (Washington DC), 250: 1259–1262, 1990.
13. Paveletich, N. P., and Pabo, C. O. Zinc finger-DNA recognition: crystal structure of the Zif268-DNA complex at 2.1 A. Science (Washington DC), 252: 809–817, 1991.
14. Haber, D. A., Sohn, R. L., Buckler, A. J., Pelletier, J., Call, K. M., and Housman D. E. Alternative splicing and genomic structure of the Wilms’ tumor gene WT1. Proc. Natl. Acad. Sci. USA, 88: 9618–9622, 1991.
15. Bickmore, W. A., Oghene, K., Little, M. H., Seawright, A., van Heyningen, V., and Hastie, N. D. Modulation of DNA binding specificity by alternative splicing of the Wilms tumor wtl gene transcript. Science (Washington DC), 257: 235–237, 1992.
16. Grubb, G. R., Yun, K., Williams, B. R. G., Eccles, M. R., and Reeve, A. E. Expression of the WT1 protein in fetal kidneys and Wilms tumors. Lab. Invest., 71: 472–479, 1994.
17. Armstrong, J. F., Prichard-Jones, K., Bickmore, W. A., Hastie, N. D., and Bard, J. B. L. The expression of the Wilms’ tumour gene, WT1, in the developing mammalian embryo. Mech. Dev., 40: 85–97, 1992.
18. Kreidberg, J. A., Sariola, H., Loring, J. M., Maeda, M., Pelletier, J., Housman, D. E., and Jaenisch, R. WT1 is required for early kidney development. Cell, 74: 679–702, 1993.
19. Bucher, P. The Eukaryotic Promoter Database EPD. Heidelberg, Germany: EMBL Nucleotide Sequence Data Library Release 40, 1992.
20. Veis, D. J., Sorenson, C. M., Shutter, J. R., and Korsmeyer, S. J. Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair. Cell, 75: 229–240, 1993.
21. Sorenson, C. M., Rogers, S. A., Korsmeyer, S. J., and Hammerman, M. R. Fulminant metanephric apoptosis and abnormal kidney development in bcl-2-deficient mice. Am. J. Physiol., 268: F73–F81, 1995.
22. Nakayama, K. Nakayama, K. I., Negishi, I., Kuida, K., Sawa, H., and Loh, D. Y. Targeted disruption of Bcl-2αβ in mice. Proc. Natl. Acad. Sci. USA, 91: 3700–3704, 1994.
23. Chandler, D., El-Naggar, A. K., Brisbay, S., Redline, R. W., and McDonnell, T. J. Apoptosis and expression of the bcl-2 proto-oncogene in the fetal and adult human kidney: evidence for the contribution of bcl-2 expression to renal carcinogenesis. Hum. Pathol., 25: 789–796, 1994.
24. Evans, G. I., Wyllie, A. H., Gilber, C. S., Littlewood, T. D., Land, H., Brooks, M., Waters, C. M., Penn, L. Z., and Hancock, D. C. Induction of apoptosis in fibroblasts by c-myc protein. Cell, 69: 119–128, 1992.
25. Davis, A. C., Wims, M., Spotts, G. D., Hans S. R., and Bradley, A. A null c-myc mutation causes lethality before 10.5 days gestation in homozygotes and reduced fertility in herterozygous female mice. Genes & Dev., 7: 671–682, 1993.
26. Trudel, M., D'Agati, V., and Costantini, F. c-myc as an inducer of polycystic kidney disease in transgenic mice. Kidney Int., 39: 665–671, 1991.
27. Nisen, P. D., Zimmerman, K. A., Cotter, S. V., Gilbert, F., and Alt F. W. Enhanced expression of the N-myc gene in Wilms’ tumors. Cancer Res., 46: 6217–6222, 1986.
28. Mugrauer, G., and Ekblom P. Contrasting expression patterns of three members of the myc family of protooncogenes in the developing and adult mouse kidney. J. Cell. Biol., 112: 13–25, 1991.
29. Lu, Q.-L., Poulsom, R., Wong, L., and Hanby, A. M. BCL-2 expression in adult and embryonic non-haematopoietic tissues. J. Pathol., 169: 431–437, 1993.
30. LeBrun, D. P., Warnke, R. A., and Cleary, M. L. Expression of bcl-2 in fetal tissues suggests a role in morphogenesis. Am. J. Pathol., 142: 743–753, 1993.
31. Oka, T., Rairkar, A., and Chen, J. H. Structural and functional analysis of the regulatory sequences of the ets-1 gene. Oncogene, 6: 2077–2083, 1991.
32. Cao, X., Koski, R. A., Gashler, A., McKiernan, M., Morris, C. F., Gaffhey, R., Hay, R. V., and Sukhatme, V. P. Identification and characterization of the Egr-1 gene product, a DNA-binding zinc finger protein induced by differentiation and growth signals. Mol. Cell. Biol., 10: 1931–1939, 1990.
33. Seto, A., Jaeger, U., Hockett, R. D., Graninger, W., Bennett, S., Goldman, P., and Korsmeyer, S. J. Alternative promoters and exons, somatic mutation and deregulation of the Bcl-2-Ig fusion gene in lymphoma. EMBO J., 7: 123–131, 1988.
34. Hall, D. J. Regulation of c-myc transcription in vitro: dependence on the guanine-rich promoter element MElal. Oncogene, 5: 47–54, 1990.
35. Bentley D. L., and Groudine, M. Sequence requirements for premature termination of transcription in the human c-myc gene. Cell, 53: 245–256, 1988.
36. Miller H., Asselin, C., Dufort, D., Yang, J.-Q., Gupta, K., Marcu, K. B., and Nepveu, A. A cis-acting element in the promoter region of the murine c-myc gene is necessary for transcriptional block. Mol. Cell. Biol., 9: 5340–5349, 1989.
37. Moberg, K. H., Logan, T. J., Tyndall, W. A., and Hall D. J. Three distinct elements within the murine c-myc promoter are required for transcription. Oncogene, 7: 411–421, 1992.
38. Hay, N., Bishop, J. M., and Levens, D. Regulatory elements that modulate expression of human c-myc. Genes & Dev., 1: 659–671, 1987.
39. Asselin, C., Nepveu, A., and Marcu, K. B. Molecular requirements for transcriptional initiation of the murine c-myc gene. Oncogene, 4: 549–558, 1989.
40. Heldin C.-H., Johnsson, A., Wennergren, S., Wernstedt, C., Betsholtz, C., and Westermark, B. A human osteosarcoma cell line secretes a growth factor structurally related to a homodimer of PDGF A-chains. Nature (Lond.), 319: 511–514, 1986.
41. Fraizer, G. E., Bowen-Pope, D. F., and Vogel, A. M. Production of platelet-derived growth factor by cultured Wilms* tumor and fetal kidneys. J. Cell. Physiol., 133: 169–174, 1987.
42. Paik, S. Rosen, N., Jung, W., You, J. M., Lippman, M. E., Perdue, J. F., and Yee, D. Expression of insulin-like growth factor II mRNA in fetal kidney and Wilms’ tumor. Lab Invest., 61: 522–526, 1989.
43. Strasser, A., Harris, A. W., Bath, M. L., and Cory S. Novel primative lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature (Lond.), 348: 331–333, 1990.
44. Marin, M. C., Hsu, B., Stephens, L. C., Brisbay, S., and McDonnell, T. J. The functional basis of c-myc and bcl-2 complementation during multistep lymphomagen-esis in vivo. Exp. Cell Res., 217: 240–247, 1995.